The depletion of copper LOX catalytic sites in the nonspecific copper chelator tetraithiomolybdate reduced the serum LOXL2 concentration in patients with moderate- to high-risk primary breast cancer in a phase II clinical trial (157) (NCT00195091). The gene discussed is LOX; the disease is breast cancer.